ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the 13 Best Low Risk High Growth Stocks to Buy. The company witnesses ...

ADMA Biologics, Inc.’s ADMA is witnessing a phenomenal run this year. Its shares have surged a whopping 262.1% in the year so far against the industry’s decline of 2.1%. The stock has been ...

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the U.S. market for plasma-derived products, should maintain momentum in the upcoming quarters. The targeted market has ...

We recently published a list of 10 Stocks Take A Shocking Nosedive. ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the worst-performing stocks on Thursday. ADMA Biologics saw its share prices decline by ...

ADMA Biologics shares were 15% higher, at $25.25, ... Its products infuse people with primary immunodeficiency with the virus-blocking antibodies their own bodies can't make.

ADMA Biologics ADMA is witnessing a phenomenal run this year. Its shares have skyrocketed 320.6% year to date against the industry’s decline of 7.4%. The stock has also outperformed the sector ...

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to ...

ADMA had filed a Biologics License Application (BLA) for its lead product candidate, RI-002, with the U.S. Food and Drug Administration (FDA), which accepted the BLA on September 18, 2015.